The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

References (15)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85
2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-98
3. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet 2016; 388: 1081-8
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39
5. Tozun N, Ozdogan O, Cakaloğlu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6
6. Available at: https://organ.saglik.gov.tr/web/. 2013
7. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239-51
8. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-67
9. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83
10. Su TH, Hu TH, Chan CY, et al. Four year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016; 36: 1755-64
11. Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 2016; 22: 319-26
12. Papatheodoridis GV, Dalekos G, Sypsa V, et al. PAGE- B predicts the risk of developin hepatocellular carcinoma in Caucasian with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-6
13. Chuang WL, Agarwal K, Hwang JS, et al. Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks. J Hepatol 2017; 66: S695
14. Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60: 1457-64
15. Papatheodoridis GV, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016; 63: